Omalizumab

Drug #2186

A monoclonal antibody used as a parenteral drug to treat severe asthma. It works by blocking your immune system's natural response to allergic triggers that can lead to an acute asthma attack. This action on your immune system (specifically immunoglobulin E-IgE), helps keep your air passages open and, over time, it keeps your asthma in better control. This medication does not work immediately and should not be used for the quick relief of an acute asthma attack.

← Previous drug Next drug →

Primary Characteristics

It belongs to Antibody pharmacological group on the basis of mechanism of action and also classified in Immune Globulin pharmacological group.

Non-proprietary name: Omalizumab.

Pharmacokinetics

Distribution: Omalizumab has a volume of distribution is 78mL/kg.

Elimination: plasma half-life is 26 days.

Indications

Omalizumab is primarily indicated in conditions like Severe persistent asthma.

Contraindications

Omalizumab is contraindicated in conditions like Hypersensitivity to any component of product.

Dosage

Omalizumab's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
262.5 mg	262.5 mg	—	SC	Should be given for 2 to 4 weeks, with dosing frequency determined by serum IgE level and weight.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Omalizumab in overdosage may give rise to further complications which include Alopecia , Thrombocytopenia , Allergic reactions .

Omalizumab is known to cause more or less tolerable side effects which are usually transient. These include Alopecia, Arthralgia, Dermatitis, dizziness, Fatigue, Hair loss, Headache, Pruritus , Sinusitis .

Warnings / Precautions

Omalizumab isn't a rescue drug and isn't intended for acute asthma attacks or status asthmaticus. Drug should not be discontinued abruptly. Patient should be monitored for severe hypersensitivity reactions.

Interference in Pathology

Omalizumab may interfere in the diagnosis of Elevated level of Serum IgE.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

150 mg/ml

Drug Classification

1.25.1.1 — Oral/Parenteral antiasthmatics

Manufacturers

Manufacturers of Omalizumab in Pakistan:

Novartis